Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018

Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Chambers, Catharine, De Serres, Gaston, Dickinson, James A, Winter, Anne-Luise, Hickman, Rebecca, Chan, Tracy, Jassem, Agatha N, Drews, Steven J, Charest, Hugues, Gubbay, Jonathan B, Bastien, Nathalie, Li, Yan, Krajden, Mel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2018
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801641/
https://www.ncbi.nlm.nih.gov/pubmed/29409570
http://dx.doi.org/10.2807/1560-7917.ES.2018.23.5.18-00035
_version_ 1783298386722553856
author Skowronski, Danuta M
Chambers, Catharine
De Serres, Gaston
Dickinson, James A
Winter, Anne-Luise
Hickman, Rebecca
Chan, Tracy
Jassem, Agatha N
Drews, Steven J
Charest, Hugues
Gubbay, Jonathan B
Bastien, Nathalie
Li, Yan
Krajden, Mel
author_facet Skowronski, Danuta M
Chambers, Catharine
De Serres, Gaston
Dickinson, James A
Winter, Anne-Luise
Hickman, Rebecca
Chan, Tracy
Jassem, Agatha N
Drews, Steven J
Charest, Hugues
Gubbay, Jonathan B
Bastien, Nathalie
Li, Yan
Krajden, Mel
author_sort Skowronski, Danuta M
collection PubMed
description Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): −14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.
format Online
Article
Text
id pubmed-5801641
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-58016412018-02-09 Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018 Skowronski, Danuta M Chambers, Catharine De Serres, Gaston Dickinson, James A Winter, Anne-Luise Hickman, Rebecca Chan, Tracy Jassem, Agatha N Drews, Steven J Charest, Hugues Gubbay, Jonathan B Bastien, Nathalie Li, Yan Krajden, Mel Euro Surveill Rapid Communication Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): −14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection. European Centre for Disease Prevention and Control (ECDC) 2018-02-01 /pmc/articles/PMC5801641/ /pubmed/29409570 http://dx.doi.org/10.2807/1560-7917.ES.2018.23.5.18-00035 Text en This article is copyright of The Authors, 2018. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Skowronski, Danuta M
Chambers, Catharine
De Serres, Gaston
Dickinson, James A
Winter, Anne-Luise
Hickman, Rebecca
Chan, Tracy
Jassem, Agatha N
Drews, Steven J
Charest, Hugues
Gubbay, Jonathan B
Bastien, Nathalie
Li, Yan
Krajden, Mel
Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
title Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
title_full Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
title_fullStr Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
title_full_unstemmed Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
title_short Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
title_sort early season co-circulation of influenza a(h3n2) and b(yamagata): interim estimates of 2017/18 vaccine effectiveness, canada, january 2018
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801641/
https://www.ncbi.nlm.nih.gov/pubmed/29409570
http://dx.doi.org/10.2807/1560-7917.ES.2018.23.5.18-00035
work_keys_str_mv AT skowronskidanutam earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT chamberscatharine earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT deserresgaston earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT dickinsonjamesa earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT winteranneluise earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT hickmanrebecca earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT chantracy earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT jassemagathan earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT drewsstevenj earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT charesthugues earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT gubbayjonathanb earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT bastiennathalie earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT liyan earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018
AT krajdenmel earlyseasoncocirculationofinfluenzaah3n2andbyamagatainterimestimatesof201718vaccineeffectivenesscanadajanuary2018

Ejemplares similares